Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| B1841005 | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This surveillance aims to figure out 1) use-results, 2) occurrence of adverse events, and 3) factors affecting safety in terms of the safety in infants starting to receive Prevenar at the age of more than 2 and less than 7 months in routine medical practice.
This surveillance will specifically focus on the occurrence of the following:
This surveillance will be conducted using a continuous surveillance system, in which each physician enrolls patients who meet the enrollment criteria continuously until the contract sample size is reached.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 7-valent vaccine injection | Infants starting to receive Prevenar at the age of more than 2 and less than 7 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 7-valent vaccine injection | Biological | For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Reactions | An adverse reaction was any untoward medical occurrence which was considered to be related to Prevenar™ (7-valent) in a participant who received Prevenar™ (7-valent). Relatedness to Prevenar™ (7-valent) was assessed by the sponsor (Pfizer Japan Inc.). | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Serious Adverse Events | A serious adverse event was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants by Month of Age at Each Vaccination Time | Number of participants was counted by month of age at each vaccination time (first to fourth). | 28 days |
| Number of Participants by Vaccination Sites at Each Vaccination Time |
Inclusion Criteria:
Exclusion Criteria:
Vaccination with Prevenar must not be given to any of the following;
Not provided
Not provided
Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yokoyama Children's Clinic | Kasuga | Fukuoka | 816-0801 | Japan |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Prevenar™ (7-valent) | Participants were vaccinated with Prevenar™ (7-valent) as follows: for primary immunization, three doses of Prevenar™ (7-valent) 0.5 mL were injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar™ (7-valent) 0.5 mL was injected subcutaneously, at least 60 days after the third dose. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
In total, 1143 participants were enrolled in this study. Of the 1143 participants, 23 participants were excluded from the baseline analysis for the reasons of protocol violation and lost to follow-up.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Prevenar™ (7-valent) | Participants were vaccinated with Prevenar™ (7-valent) as follows: for primary immunization, three doses of Prevenar™ (7-valent) 0.5 mL were injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar™ (7-valent) 0.5 mL was injected subcutaneously, at least 60 days after the third dose. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Participants were vaccinated with Prevenar™ (7-valent) according to the Japanese package insert (age in months at the first vaccination). |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Adverse Reactions | An adverse reaction was any untoward medical occurrence which was considered to be related to Prevenar™ (7-valent) in a participant who received Prevenar™ (7-valent). Relatedness to Prevenar™ (7-valent) was assessed by the sponsor (Pfizer Japan Inc.). | The safety analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | participants | 28 days |
|
28 days
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Prevenar™ (7-valent) | Participants were vaccinated with Prevenar™ (7-valent) as follows: for primary immunization, three doses of Prevenar™ (7-valent) 0.5 mL were injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar™ (7-valent) 0.5 mL was injected subcutaneously, at least 60 days after the third dose. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cellulitis orbital | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bronchitis | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D000069443 | Heptavalent Pneumococcal Conjugate Vaccine |
| ID | Term |
|---|---|
| D022242 | Pneumococcal Vaccines |
| D022541 | Streptococcal Vaccines |
| D001428 | Bacterial Vaccines |
| D014612 | Vaccines |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Number of Participants With Injection Site Reactions | Injection site reactions (erythema, induration, tenderness, and warmth) were defined by preferred terms of MedDRA/J version 16.0 as follows: erythema for "injection site erythema"; induration for "injection site erythema" and "injection site swelling"; tenderness for "injection site pain"; and warmth for "injection site warmth". | 28 days |
| Number of Participants With Systemic Reactions (Pyrexia of Over 39C°) by Pattern of Concomitant Vaccination | Number of participants with pyrexia (MedDRA/J version 16.0 preferred terms) of over 39C° at each vaccination time (first to fourth) was counted by each pattern of concomitant vaccination. The concomitant vaccines (CVs) used in this survey were; vaccines against Haemophilus influenzae type b (Hib), diphtheria and tetanus toxoids and pertussis (DPT), measles and rubella (MR), influenza (Flu), bacille Calmette-Guérin (BCG), vesicular stomatitis Indiana virus (VSV), Mumps, Hepatitis B (HB); and oral polio vaccine (OPV) and inactivated polio vaccine (IPV). | 28 days |
| Number of Participants With Systemic Reactions (Pyrexia) by Pattern of Concomitant Vaccination | Number of participants with pyrexia (MedDRA/J version 16.0 preferred terms) at each vaccination time (first to fourth) was counted by each pattern of concomitant vaccination. The concomitant vaccines (CVs) used in this survey were; vaccines against Haemophilus influenzae type b (Hib), diphtheria and tetanus toxoids and pertussis (DPT), measles and rubella (MR), influenza (Flu), bacille Calmette-Guérin (BCG), vesicular stomatitis Indiana virus (VSV), Mumps, Hepatitis B (HB); and oral polio vaccine (OPV) and inactivated polio vaccine (IPV). | 28 days |
Number of participants was counted by vaccination sites at each vaccination time (first to fourth).
| 28 days |
| Number of Participants by Pattern of Concomitant Vaccines | Number of participants was counted by each pattern of concomitant vaccination at each vaccination time (first to fourth). The concomitant vaccines (CVs) used were; vaccines against Haemophilus influenzae type b (Hib), diphtheria and tetanus toxoids and pertussis (DPT), measles and rubella (MR), influenza (Flu), bacille Calmette-Guérin (BCG), vesicular stomatitis Indiana virus (VSV), Mumps, Hepatitis B (HB); and oral polio vaccine (OPV) and inactivated polio vaccine (IPV). | 28 days |
| Number of Participants by Pattern of Concomitant Vaccination Sites | Number of participants was counted by each pattern of concomitant vaccination sites at each vaccination time (first to fourth). Vaccination sites of each concomitant vaccines and that of Prevenar™ (7-valent) (PVN7) were defined as follows: upper arm, UA; upper buttock, UB; femour, F; and oral route, O; R, right; L, left; same, same side of the vaccination site of PVN7; and other, other side of the vaccination site of PVN7. PVN7 was vaccinated at upper arm if not stated otherwise. The 1st to 4th represents the first to fourth vaccination of PVN7, respectively. | 28 days |
| Number |
| Participants |
|
| Sex: Female, Male | Participants were vaccinated with Prevenar™ (7-valent) according to the Japanese package insert. | Count of Participants | Participants |
|
|
|
| Secondary | Number of Participants With Serious Adverse Events | A serious adverse event was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | The safety analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | participants | 28 days |
|
|
|
| Secondary | Number of Participants With Injection Site Reactions | Injection site reactions (erythema, induration, tenderness, and warmth) were defined by preferred terms of MedDRA/J version 16.0 as follows: erythema for "injection site erythema"; induration for "injection site erythema" and "injection site swelling"; tenderness for "injection site pain"; and warmth for "injection site warmth". | The safety analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | Participants | 28 days |
|
|
|
| Secondary | Number of Participants With Systemic Reactions (Pyrexia of Over 39C°) by Pattern of Concomitant Vaccination | Number of participants with pyrexia (MedDRA/J version 16.0 preferred terms) of over 39C° at each vaccination time (first to fourth) was counted by each pattern of concomitant vaccination. The concomitant vaccines (CVs) used in this survey were; vaccines against Haemophilus influenzae type b (Hib), diphtheria and tetanus toxoids and pertussis (DPT), measles and rubella (MR), influenza (Flu), bacille Calmette-Guérin (BCG), vesicular stomatitis Indiana virus (VSV), Mumps, Hepatitis B (HB); and oral polio vaccine (OPV) and inactivated polio vaccine (IPV). | The safety analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | Participants | 28 days |
|
|
|
| Secondary | Number of Participants With Systemic Reactions (Pyrexia) by Pattern of Concomitant Vaccination | Number of participants with pyrexia (MedDRA/J version 16.0 preferred terms) at each vaccination time (first to fourth) was counted by each pattern of concomitant vaccination. The concomitant vaccines (CVs) used in this survey were; vaccines against Haemophilus influenzae type b (Hib), diphtheria and tetanus toxoids and pertussis (DPT), measles and rubella (MR), influenza (Flu), bacille Calmette-Guérin (BCG), vesicular stomatitis Indiana virus (VSV), Mumps, Hepatitis B (HB); and oral polio vaccine (OPV) and inactivated polio vaccine (IPV). | The safety analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | participants | 28 days |
|
|
|
| Other Pre-specified | Number of Participants by Month of Age at Each Vaccination Time | Number of participants was counted by month of age at each vaccination time (first to fourth). | The analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | Participants | 28 days |
|
|
|
| Other Pre-specified | Number of Participants by Vaccination Sites at Each Vaccination Time | Number of participants was counted by vaccination sites at each vaccination time (first to fourth). | The analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | Participants | 28 days |
|
|
|
| Other Pre-specified | Number of Participants by Pattern of Concomitant Vaccines | Number of participants was counted by each pattern of concomitant vaccination at each vaccination time (first to fourth). The concomitant vaccines (CVs) used were; vaccines against Haemophilus influenzae type b (Hib), diphtheria and tetanus toxoids and pertussis (DPT), measles and rubella (MR), influenza (Flu), bacille Calmette-Guérin (BCG), vesicular stomatitis Indiana virus (VSV), Mumps, Hepatitis B (HB); and oral polio vaccine (OPV) and inactivated polio vaccine (IPV). | The analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | participants | 28 days |
|
|
|
| Other Pre-specified | Number of Participants by Pattern of Concomitant Vaccination Sites | Number of participants was counted by each pattern of concomitant vaccination sites at each vaccination time (first to fourth). Vaccination sites of each concomitant vaccines and that of Prevenar™ (7-valent) (PVN7) were defined as follows: upper arm, UA; upper buttock, UB; femour, F; and oral route, O; R, right; L, left; same, same side of the vaccination site of PVN7; and other, other side of the vaccination site of PVN7. PVN7 was vaccinated at upper arm if not stated otherwise. The 1st to 4th represents the first to fourth vaccination of PVN7, respectively. | The analysis population comprised of participants who had received Prevenar™ (7-valent) at least once and provided the safety data and who did not meet the exclusion criteria for the safety analysis. | Posted | Number | participants | 28 days |
|
|
|
| 20 |
| 1,120 |
| 464 |
| 1,120 |
| Gastroenteritis | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Gastroenteritis adenovirus | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Gastroenteritis rotavirus | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Otitis media | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Otitis media acute | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Respiratory syncytial virus bronchiolitis | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Respiratory syncytial virus infection | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Astrocytoma malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA/J16.0 | Non-systematic Assessment |
|
| Feeding disorder neonatal | Metabolism and nutrition disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Kawasaki's disease | Vascular disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Inguinal hernia | Gastrointestinal disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Pyrexia | General disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Injection site swelling | General disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Exanthema subitum | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Hand-foot-and-mouth disease | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Rhinitis | Infections and infestations | MedDRA/J16.0 | Non-systematic Assessment |
|
| Conjunctivitis | Eye disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Dermatitis diaper | Skin and subcutaneous tissue disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Eczema | Skin and subcutaneous tissue disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Asteatosis | Skin and subcutaneous tissue disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Injection site erythema | General disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Injection site swelling | General disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
| Pyrexia | General disorders | MedDRA/J16.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D001688 |
| Biological Products |
| D045424 | Complex Mixtures |
| D017778 | Vaccines, Combined |
| Title | Measurements |
|---|---|
|
| Warmth |
|
| Title | Measurements |
|---|---|
|
| No CVs: 4th (n =450) |
|
| Hib: 1st (n =327) |
|
| Hib: 2nd (n =207) |
|
| Hib: 3rd (n =303) |
|
| Hib: 4th (n =39) |
|
| DPT: 1st (n =176) |
|
| DPT: 2nd (n =138) |
|
| DPT: 3rd (n =72) |
|
| DPT: 4th (n =8) |
|
| MR: 1st (n =0) |
|
| MR: 2nd (n =0) |
|
| MR: 3rd (n =1) |
|
| MR: 4th (n =179) |
|
| Flu: 1st (n =0) |
|
| Flu: 2nd (n =0) |
|
| Flu: 3rd (n =3) |
|
| Flu: 4th (n =29) |
|
| BCG: 1st (n =10) |
|
| BCG: 2nd (n =6) |
|
| BCG: 3rd (n =3) |
|
| BCG: 4th (n =0) |
|
| VSV: 1st (n =0) |
|
| VSV: 2nd (n =0) |
|
| VSV: 3rd (n =0) |
|
| VSV: 4th (n =10) |
|
| Mumps: 1st (n =0) |
|
| Mumps: 2nd (n =0) |
|
| Mumps: 3rd (n =0) |
|
| Mumps: 4th (n =3) |
|
| HB: 1st (n =0) |
|
| HB: 2nd (n =1) |
|
| HB: 3rd (n =0) |
|
| HB: 4th (n =3) |
|
| OPV: 1st (n =1) |
|
| OPV: 2nd (n =1) |
|
| OPV: 3rd (n =0) |
|
| OPV: 4th (n =2) |
|
| IPV: 1st (n =0) |
|
| IPV: 2nd (n =0) |
|
| IPV: 3rd (n =0) |
|
| IPV: 4th (n =4) |
|
| DPT + Hib: 1st (n =412) |
|
| DPT + Hib: 2nd (n =556) |
|
| DPT + Hib: 3rd (n =420) |
|
| DPT + Hib: 4th (n =34) |
|
| Hib + MR: 1st (n =0) |
|
| Hib + MR: 2nd (n =1) |
|
| Hib + MR: 3rd (n =1) |
|
| Hib + MR: 4th (n =12) |
|
| Hib + Flu: 1st (n =0) |
|
| Hib + Flu: 2nd (n =2) |
|
| Hib + Flu: 3rd (n =1) |
|
| Hib + Flu: 4th (n =5) |
|
| Hib + HB: 1st (n =1) |
|
| Hib + HB: 2nd (n =1) |
|
| Hib + HB: 3rd (n =0) |
|
| Hib + HB: 4th (n =0) |
|
| BCG + Hib: 1st (n =8) |
|
| BCG + Hib: 2nd (n =2) |
|
| BCG + Hib: 3rd (n =3) |
|
| BCG + Hib: 4th (n =0) |
|
| OPV + Hib: 1st (n =1) |
|
| OPV + Hib: 2nd (n =0) |
|
| OPV + Hib: 3rd (n =4) |
|
| OPV + Hib: 4th (n =0) |
|
| DPT + MR: 1st (n =0) |
|
| DPT + MR: 2nd (n =1) |
|
| DPT + MR: 3rd (n =0) |
|
| DPT + MR: 4th (n =0) |
|
| DPT + Flu: 1st (n =0) |
|
| DPT + Flu: 2nd (n =1) |
|
| DPT + Flu: 3rd (n =0) |
|
| DPT + Flu: 4th (n =1) |
|
| DPT + VSV: 1st (n =0) |
|
| DPT + VSV: 2nd (n =0) |
|
| DPT + VSV: 3rd (n =0) |
|
| DPT + VSV: 4th (n =2) |
|
| DPT + Mumps: 1st (n =0) |
|
| DPT + Mumps: 2nd (n =0) |
|
| DPT + Mumps: 3rd (n =0) |
|
| DPT + Mumps: 4th (n =0) |
|
| MR + VSV: 1st (n =0) |
|
| MR + VSV: 2nd (n =0) |
|
| MR + VSV: 3rd (n =0) |
|
| MR + VSV: 4th (n =3) |
|
| MR + Mumps: 1st (n =0) |
|
| MR + Mumps: 2nd (n =0) |
|
| MR + Mumps: 3rd (n =0) |
|
| MR + Mumps: 4th (n =2) |
|
| MR + HB: 1st (n =0) |
|
| MR + HB: 2nd (n =0) |
|
| MR + HB: 3rd (n =0) |
|
| MR + HB: 4th (n =1) |
|
| Flu + MR: 1st (n =0) |
|
| Flu + MR: 2nd (n =0) |
|
| Flu + MR: 3rd (n =0) |
|
| Flu + MR: 4th (n =3) |
|
| Flu + Mumps: 1st (n =0) |
|
| Flu + Mumps: 2nd (n =0) |
|
| Flu + Mumps: 3rd (n =0) |
|
| Flu + Mumps: 4th (n =1) |
|
| VSV + Mumps: 1st (n =0) |
|
| VSV + Mumps: 2nd (n =0) |
|
| VSV + Mumps: 3rd (n =0) |
|
| VSV + Mumps: 4th (n =4) |
|
| MR + VSV + Mumps: 1st (n =0) |
|
| MR + VSV + Mumps: 2nd (n =0) |
|
| MR + VSV + Mumps: 3rd (n =0) |
|
| MR + VSV + Mumps: 4th (n =34) |
|
| DPT + Hib + MR: 1st (n =0) |
|
| DPT + Hib + MR: 2nd (n =0) |
|
| DPT + Hib + MR: 3rd (n =0) |
|
| DPT + Hib + MR: 4th (n =1) |
|
| Hib + MR + VSV: 1st (n =0) |
|
| Hib + MR + VSV: 2nd (n =0) |
|
| Hib + MR + VSV: 3rd (n =0) |
|
| Hib + MR + VSV: 4th (n =1) |
|
| DPT + Hib + Mumps: 1st (n =0) |
|
| DPT + Hib + Mumps: 2nd (n =0) |
|
| DPT + Hib + Mumps: 3rd (n =1) |
|
| DPT + Hib + Mumps: 4th (n =0) |
|
| DPT + Hib + HB: 1st (n =0) |
|
| DPT + Hib + HB: 2nd (n =0) |
|
| DPT + Hib + HB: 3rd (n =1) |
|
| DPT + Hib + HB: 4th (n =0) |
|
| DPT + Hib + IPV: 1st (n =0) |
|
| DPT + Hib + IPV: 2nd (n =0) |
|
| DPT + Hib + IPV: 3rd (n =1) |
|
| DPT + Hib + IPV: 4th (n =0) |
|
| VSV + Mumps + IPV: 1st (n =0) |
|
| VSV + Mumps + IPV: 2nd (n =0) |
|
| VSV + Mumps + IPV: 3rd (n =0) |
|
| VSV + Mumps + IPV: 4th (n =2) |
|
| Hib + MR + VSV + Mumps: 1st (n =0) |
|
| Hib + MR + VSV + Mumps: 2nd (n =0) |
|
| Hib + MR + VSV + Mumps: 3rd (n =0) |
|
| Hib + MR + VSV + Mumps: 4th (n =1) |
|
| Hib + MR + Mumps + IPV: 1st (n =0) |
|
| Hib + MR + Mumps + IPV: 2nd (n =0) |
|
| Hib + MR + Mumps + IPV: 3rd (n =0) |
|
| Hib + MR + Mumps + IPV: 4th (n =1) |
|
| MR + VSV + Mumps + HB: 1st (n =0) |
|
| MR + VSV + Mumps + HB: 2nd (n =0) |
|
| MR + VSV + Mumps + HB: 3rd (n =0) |
|
| MR + VSV + Mumps + HB: 4th (n =1) |
|
| Title | Measurements |
|---|---|
|
| No CVs: 4th (n =450) |
|
| Hib: 1st (n =327) |
|
| Hib: 2nd (n =207) |
|
| Hib: 3rd (n =303) |
|
| Hib: 4th (n =39) |
|
| DPT: 1st (n =176) |
|
| DPT: 2nd (n =138) |
|
| DPT: 3rd (n =72) |
|
| DPT: 4th (n =8) |
|
| MR: 1st (n =0) |
|
| MR: 2nd (n =0) |
|
| MR: 3rd (n =1) |
|
| MR: 4th (n =179) |
|
| Flu: 1st (n =0) |
|
| Flu: 2nd (n =0) |
|
| Flu: 3rd (n =3) |
|
| Flu: 4th (n =29) |
|
| BCG: 1st (n =10) |
|
| BCG: 2nd (n =6) |
|
| BCG: 3rd (n =3) |
|
| BCG: 4th (n =0) |
|
| VSV: 1st (n =0) |
|
| VSV: 2nd (n =0) |
|
| VSV: 3rd (n =0) |
|
| VSV: 4th (n =10) |
|
| Mumps: 1st (n =0) |
|
| Mumps: 2nd (n =0) |
|
| Mumps: 3rd (n =0) |
|
| Mumps: 4th (n =3) |
|
| HB: 1st (n =0) |
|
| HB: 2nd (n =1) |
|
| HB: 3rd (n =0) |
|
| HB: 4th (n =3) |
|
| OPV: 1st (n =1) |
|
| OPV: 2nd (n =1) |
|
| OPV: 3rd (n =0) |
|
| OPV: 4th (n =2) |
|
| IPV: 1st (n =0) |
|
| IPV: 2nd (n =0) |
|
| IPV: 3rd (n =0) |
|
| IPV: 4th (n =4) |
|
| DPT + Hib: 1st (n =412) |
|
| DPT + Hib: 2nd (n =556) |
|
| DPT + Hib: 3rd (n =420) |
|
| DPT + Hib: 4th (n =34) |
|
| Hib + MR: 1st (n =0) |
|
| Hib + MR: 2nd (n =1) |
|
| Hib + MR: 3rd (n =1) |
|
| Hib + MR: 4th (n =12) |
|
| Hib + Flu: 1st (n =0) |
|
| Hib + Flu: 2nd (n =2) |
|
| Hib + Flu: 3rd (n =1) |
|
| Hib + Flu: 4th (n =5) |
|
| Hib + HB: 1st (n =1) |
|
| Hib + HB: 2nd (n =1) |
|
| Hib + HB: 3rd (n =0) |
|
| Hib + HB: 4th (n =0) |
|
| BCG + Hib: 1st (n =8) |
|
| BCG + Hib: 2nd (n =2) |
|
| BCG + Hib: 3rd (n =3) |
|
| BCG + Hib: 4th (n =0) |
|
| OPV + Hib: 1st (n =1) |
|
| OPV + Hib: 2nd (n =0) |
|
| OPV + Hib: 3rd (n =4) |
|
| OPV + Hib: 4th (n =0) |
|
| DPT + MR: 1st (n =0) |
|
| DPT + MR: 2nd (n =1) |
|
| DPT + MR: 3rd (n =0) |
|
| DPT + MR: 4th (n =0) |
|
| DPT + Flu: 1st (n =0) |
|
| DPT + Flu: 2nd (n =1) |
|
| DPT + Flu: 3rd (n =0) |
|
| DPT + Flu: 4th (n =1) |
|
| DPT + VSV: 1st (n =0) |
|
| DPT + VSV: 2nd (n =0) |
|
| DPT + VSV: 3rd (n =0) |
|
| DPT + VSV: 4th (n =2) |
|
| DPT + Mumps: 1st (n =0) |
|
| DPT + Mumps: 2nd (n =0) |
|
| DPT + Mumps: 3rd (n =0) |
|
| DPT + Mumps: 4th (n =0) |
|
| MR + VSV: 1st (n =0) |
|
| MR + VSV: 2nd (n =0) |
|
| MR + VSV: 3rd (n =0) |
|
| MR + VSV: 4th (n =3) |
|
| MR + Mumps: 1st (n =0) |
|
| MR + Mumps: 2nd (n =0) |
|
| MR + Mumps: 3rd (n =0) |
|
| MR + Mumps: 4th (n =2) |
|
| MR + HB: 1st (n =0) |
|
| MR + HB: 2nd (n =0) |
|
| MR + HB: 3rd (n =0) |
|
| MR + HB: 4th (n =1) |
|
| Flu + MR: 1st (n =0) |
|
| Flu + MR: 2nd (n =0) |
|
| Flu + MR: 3rd (n =0) |
|
| Flu + MR: 4th (n =3) |
|
| Flu + Mumps: 1st (n =0) |
|
| Flu + Mumps: 2nd (n =0) |
|
| Flu + Mumps: 3rd (n =0) |
|
| Flu + Mumps: 4th (n =1) |
|
| VSV + Mumps: 1st (n =0) |
|
| VSV + Mumps: 2nd (n =0) |
|
| VSV + Mumps: 3rd (n =0) |
|
| VSV + Mumps: 4th (n =4) |
|
| MR + VSV + Mumps: 1st (n =0) |
|
| MR + VSV + Mumps: 2nd (n =0) |
|
| MR + VSV + Mumps: 3rd (n =0) |
|
| MR + VSV + Mumps: 4th (n =34) |
|
| DPT + Hib + MR: 1st (n =0) |
|
| DPT + Hib + MR: 2nd (n =0) |
|
| DPT + Hib + MR: 3rd (n =0) |
|
| DPT + Hib + MR: 4th (n =1) |
|
| Hib + MR + VSV: 1st (n =0) |
|
| Hib + MR + VSV: 2nd (n =0) |
|
| Hib + MR + VSV: 3rd (n =0) |
|
| Hib + MR + VSV: 4th (n =1) |
|
| DPT + Hib + Mumps: 1st (n =0) |
|
| DPT + Hib + Mumps: 2nd (n =0) |
|
| DPT + Hib + Mumps: 3rd (n =1) |
|
| DPT + Hib + Mumps: 4th (n =0) |
|
| DPT + Hib + HB: 1st (n =0) |
|
| DPT + Hib + HB: 2nd (n =0) |
|
| DPT + Hib + HB: 3rd (n =1) |
|
| DPT + Hib + HB: 4th (n =0) |
|
| DPT + Hib + IPV: 1st (n =0) |
|
| DPT + Hib + IPV: 2nd (n =0) |
|
| DPT + Hib + IPV: 3rd (n =1) |
|
| DPT + Hib + IPV: 4th (n =0) |
|
| VSV + Mumps + IPV: 1st (n =0) |
|
| VSV + Mumps + IPV: 2nd (n =0) |
|
| VSV + Mumps + IPV: 3rd (n =0) |
|
| VSV + Mumps + IPV: 4th (n =2) |
|
| Hib + MR + VSV + Mumps: 1st (n =0) |
|
| Hib + MR + VSV + Mumps: 2nd (n =0) |
|
| Hib + MR + VSV + Mumps: 3rd (n =0) |
|
| Hib + MR + VSV + Mumps: 4th (n =1) |
|
| Hib + MR + Mumps + IPV: 1st (n =0) |
|
| Hib + MR + Mumps + IPV: 2nd (n =0) |
|
| Hib + MR + Mumps + IPV: 3rd (n =0) |
|
| Hib + MR + Mumps + IPV: 4th (n =1) |
|
| MR + VSV + Mumps + HB: 1st (n =0) |
|
| MR + VSV + Mumps + HB: 2nd (n =0) |
|
| MR + VSV + Mumps + HB: 3rd (n =0) |
|
| MR + VSV + Mumps + HB: 4th (n =1) |
|
| Title | Measurements |
|---|---|
|
| 2 to less than 3 months: 4th (n =836) |
|
| 3 to less than 4 months: 1st (n =1120) |
|
| 3 to less than 4 months: 2nd (n =1083) |
|
| 3 to less than 4 months: 3rd (n =1017) |
|
| 3 to less than 4 months: 4th (n =836) |
|
| 4 to less than 5 months: 1st (n =1120) |
|
| 4 to less than 5 months: 2nd (n =1083) |
|
| 4 to less than 5 months: 3rd (n =1017) |
|
| 4 to less than 5 months: 4th (n =836) |
|
| 5 to less than 6 months: 1st (n =1120) |
|
| 5 to less than 6 months: 2nd (n =1083) |
|
| 5 to less than 6 months: 3rd (n =1017) |
|
| 5 to less than 6 months: 4th (n =836) |
|
| 6 to less than 7 months: 1st (n =1120) |
|
| 6 to less than 7 months: 2nd (n =1083) |
|
| 6 to less than 7 months: 3rd (n =1017) |
|
| 6 to less than 7 months: 4th (n =836) |
|
| 7 to less than 8 months: 1st (n =1120) |
|
| 7 to less than 8 months: 2nd (n =1083) |
|
| 7 to less than 8 months: 3rd (n =1017) |
|
| 7 to less than 8 months: 4th (n =836) |
|
| 8 to less than 9 months: 1st (n =1120) |
|
| 8 to less than 9 months: 2nd (n =1083) |
|
| 8 to less than 9 months: 3rd (n =1017) |
|
| 8 to less than 9 months: 4th (n =836) |
|
| 9 to less than 10 months: 1st (n =1120) |
|
| 9 to less than 10 months: 2nd (n =1083) |
|
| 9 to less than 10 months: 3rd (n =1017) |
|
| 9 to less than 10 months: 4th (n =836) |
|
| 10 to less than 11 months: 1st (n =1120) |
|
| 10 to less than 11 months: 2nd (n =1083) |
|
| 10 to less than 11 months: 3rd (n =1017) |
|
| 10 to less than 11 months: 4th (n =836) |
|
| 11 to less than 12 months: 1st (n =1120) |
|
| 11 to less than 12 months: 2nd (n =1083) |
|
| 11 to less than 12 months: 3rd (n =1017) |
|
| 11 to less than 12 months: 4th (n =836) |
|
| 12 to less than 16 months: 1st (n =1120) |
|
| 12 to less than 16 months: 2nd (n =1083) |
|
| 12 to less than 16 months: 3rd (n =1017) |
|
| 12 to less than 16 months: 4th (n =836) |
|
| 16 to less than 18 months: 1st (n =1120) |
|
| 16 to less than 18 months: 2nd (n =1083) |
|
| 16 to less than 18 months: 3rd (n =1017) |
|
| 16 to less than 18 months: 4th (n =836) |
|
| 18 to less than 24 months: 1st (n =1120) |
|
| 18 to less than 24 months: 2nd (n =1083) |
|
| 18 to less than 24 months: 3rd (n =1017) |
|
| 18 to less than 24 months: 4th (n =836) |
|
| 24 months and order: 1st (n =1120) |
|
| 24 months and order: 2nd (n =1083) |
|
| 24 months and order: 3rd (n =1017) |
|
| 24 months and order: 4th (n =836) |
|
| Unknown: 1st (n =1120) |
|
| Unknown: 2nd (n =1083) |
|
| Unknown: 3rd (n =1017) |
|
| Unknown: 4th (n =836) |
|
| Title | Measurements |
|---|---|
|
| Upper Arm: 4th (n =836) |
|
| Other: 1st (n =1120) |
|
| Other: 2nd (n =1083) |
|
| Other: 3rd (n =1017) |
|
| Other: 4th (n= 836) |
|
| Title | Measurements |
|---|---|
|
| No CVs: 4th (n =836) |
|
| Hib: 1st (n =1120) |
|
| Hib: 2nd (n =1083) |
|
| Hib: 3rd (n =1017) |
|
| Hib: 4th (n =836) |
|
| DPT: 1st (n =1120) |
|
| DPT: 2nd (n =1083) |
|
| DPT: 3rd (n =1017) |
|
| DPT: 4th (n =836) |
|
| MR: 1st (n =1120) |
|
| MR: 2nd (n =1083) |
|
| MR: 3rd (n =1017) |
|
| MR: 4th (n =836) |
|
| Flu: 1st (n =1120) |
|
| Flu: 2nd (n =1083) |
|
| Flu: 3rd (n =1017) |
|
| Flu: 4th (n =836) |
|
| BCG: 1st (n =1120) |
|
| BCG: 2nd (n =1083) |
|
| BCG: 3rd (n =1017) |
|
| BCG: 4th (n =836) |
|
| VSV: 1st (n =1120) |
|
| VSV: 2nd (n =1083) |
|
| VSV: 3rd (n =1017) |
|
| VSV: 4th (n =836) |
|
| Mumps: 1st (n =1120) |
|
| Mumps: 2nd (n =1083) |
|
| Mumps: 3rd (n =1017) |
|
| Mumps: 4th (n =836) |
|
| HB: 1st (n =1120) |
|
| HB: 2nd (n =1083) |
|
| HB: 3rd (n =1017) |
|
| HB: 4th (n =836) |
|
| OPV: 1st (n =1120) |
|
| OPV: 2nd (n =1083) |
|
| OPV: 3rd (n =1017) |
|
| OPV: 4th (n =836) |
|
| IPV: 1st (n =1120) |
|
| IPV: 2nd (n =1083) |
|
| IPV: 3rd (n =1017) |
|
| IPV: 4th (n =836) |
|
| DPT + Hib: 1st (n =1120) |
|
| DPT + Hib: 2nd (n =1083) |
|
| DPT + Hib: 3rd (n =1017) |
|
| DPT + Hib: 4th (n =836) |
|
| Hib + MR: 1st (n =1120) |
|
| Hib + MR: 2nd (n =1083) |
|
| Hib + MR: 3rd (n =1017) |
|
| Hib + MR: 4th (n =836) |
|
| Hib + Flu: 1st (n =1120) |
|
| Hib + Flu: 2nd (n =1083) |
|
| Hib + Flu: 3rd (n =1017) |
|
| Hib + Flu: 4th (n =836) |
|
| Hib + HB: 1st (n =1120) |
|
| Hib + HB: 2nd (n =1083) |
|
| Hib + HB: 3rd (n =1017) |
|
| Hib + HB: 4th (n =836) |
|
| BCG + Hib: 1st (n =1120) |
|
| BCG + Hib: 2nd (n =1083) |
|
| BCG + Hib: 3rd (n =1017) |
|
| BCG + Hib: 4th (n =836) |
|
| OPV + Hib: 1st (n =1120) |
|
| OPV + Hib: 2nd (n =1083) |
|
| OPV + Hib: 3rd (n =1017) |
|
| OPV + Hib: 4th (n =836) |
|
| DPT + MR: 1st (n =1120) |
|
| DPT + MR: 2nd (n =1083) |
|
| DPT + MR: 3rd (n =1017) |
|
| DPT + MR: 4th (n =836) |
|
| DPT + Flu: 1st (n =1120) |
|
| DPT + Flu: 2nd (n =1083) |
|
| DPT + Flu: 3rd (n =1017) |
|
| DPT + Flu: 4th (n =836) |
|
| DPT + VSV: 1st (n =1120) |
|
| DPT + VSV: 2nd (n =1083) |
|
| DPT + VSV: 3rd (n =1017) |
|
| DPT + VSV: 4th (n =836) |
|
| DPT + Mumps: 1st (n =1120) |
|
| DPT + Mumps: 2nd (n =1083) |
|
| DPT + Mumps: 3rd (n =1017) |
|
| DPT + Mumps: 4th (n =836) |
|
| MR + VSV: 1st (n =1120) |
|
| MR + VSV: 2nd (n =1083) |
|
| MR + VSV: 3rd (n =1017) |
|
| MR + VSV: 4th (n =836) |
|
| MR + Mumps: 1st (n =1120) |
|
| MR + Mumps: 2nd (n =1083) |
|
| MR + Mumps: 3rd (n =1017) |
|
| MR + Mumps: 4th (n =836) |
|
| MR + HB: 1st (n =1120) |
|
| MR + HB: 2nd (n =1083) |
|
| MR + HB: 3rd (n =1017) |
|
| MR + HB: 4th (n =836) |
|
| Flu + MR: 1st (n =1120) |
|
| Flu + MR: 2nd (n =1083) |
|
| Flu + MR: 3rd (n =1017) |
|
| Flu + MR: 4th (n =836) |
|
| Flu + Mumps: 1st (n =1120) |
|
| Flu + Mumps: 2nd (n =1083) |
|
| Flu + Mumps: 3rd (n =1017) |
|
| Flu + Mumps: 4th (n =836) |
|
| VSV + Mumps: 1st (n =1120) |
|
| VSV + Mumps: 2nd (n =1083) |
|
| VSV + Mumps: 3rd (n =1017) |
|
| VSV + Mumps: 4th (n =836) |
|
| MR + VSV + Mumps: 1st (n =1120) |
|
| MR + VSV + Mumps: 2nd (n =1083) |
|
| MR + VSV + Mumps: 3rd (n =1017) |
|
| MR + VSV + Mumps: 4th (n =836) |
|
| DPT + Hib + MR: 1st (n =1120) |
|
| DPT + Hib + MR: 2nd (n =1083) |
|
| DPT + Hib + MR: 3rd (n =1017) |
|
| DPT + Hib + MR: 4th (n =836) |
|
| Hib + MR + VSV: 1st (n =1120) |
|
| Hib + MR + VSV: 2nd (n =1083) |
|
| Hib + MR + VSV: 3rd (n =1017) |
|
| Hib + MR + VSV: 4th (n =836) |
|
| DPT + Hib + Mumps: 1st (n =1120) |
|
| DPT + Hib + Mumps: 2nd (n =1083) |
|
| DPT + Hib + Mumps: 3rd (n =1017) |
|
| DPT + Hib + Mumps: 4th (n =836) |
|
| DPT + Hib + HB: 1st (n =1120) |
|
| DPT + Hib + HB: 2nd (n =1083) |
|
| DPT + Hib + HB: 3rd (n =1017) |
|
| DPT + Hib + HB: 4th (n =836) |
|
| DPT + Hib + IPV: 1st (n =1120) |
|
| DPT + Hib + IPV: 2nd (n =1083) |
|
| DPT + Hib + IPV: 3rd (n =1017) |
|
| DPT + Hib + IPV: 4th (n =836) |
|
| VSV + Mumps + IPV: 1st (n =1120) |
|
| VSV + Mumps + IPV: 2nd (n =1083) |
|
| VSV + Mumps + IPV: 3rd (n =1017) |
|
| VSV + Mumps + IPV: 4th (n =836) |
|
| Hib + MR + VSV + Mumps: 1st (n =1120) |
|
| Hib + MR + VSV + Mumps: 2nd (n =1083) |
|
| Hib + MR + VSV + Mumps: 3rd (n =1017) |
|
| Hib + MR + VSV + Mumps: 4th (n =836) |
|
| Hib + MR + Mumps + IPV: 1st (n =1120) |
|
| HIb + MR + Mumps + IPV: 2nd (n =1083) |
|
| Hib + MR + Mumps + IPV: 3rd (n =1017) |
|
| Hib + MR + Mumps + IPV: 4th (n =836) |
|
| MR + VSV + Mumps + HB: 1st (n =1120) |
|
| MR + VSV + Mumps + HB: 2nd (n =1083) |
|
| MR + VSV + Mumps + HB: 3rd (n =1017) |
|
| MR + VSV + Mumps + HB: 4th (n =836) |
|
| Title | Measurements |
|---|---|
|
| No CVs: 4th (n =836) |
|
| CV, same UA: 1st (n =1120) |
|
| CV, same UA: 2nd (n =1083) |
|
| CV, same UA: 3rd (n =1017) |
|
| CV, same UA: 4th (n =836) |
|
| CV, other UA: 1st (n =1120) |
|
| CV, other UA: 2nd (n =1083) |
|
| CV, other UA: 3rd (n =1017) |
|
| CV, other UA: 4th (n =836) |
|
| CV, same F: 1st (n =1120) |
|
| CV, same F: 2nd (n =1083) |
|
| CV, same F: 3rd (n =1017) |
|
| CV, same F: 4th (n =836) |
|
| CV, O: 1st (n =1120) |
|
| CV, O: 2nd (n =1083) |
|
| CV, O: 3rd (n =1017) |
|
| CV, O: 4th (n =836) |
|
| CVs, same UA X2: 1st (n =1120) |
|
| CVs, same UA X2: 2nd (n =1083) |
|
| CVs, same UA X2: 3rd (n =1017) |
|
| CVs, same UA X2: 4th (n =836) |
|
| CVs, same UA + other UA: 1st (n =1120) |
|
| CVs, same UA + other UA: 2nd (n =1083) |
|
| CVs, same UA + other UA: 3rd (n =1017) |
|
| CVs, same UA + other UA: 4th (n =836) |
|
| CVs, other UA X2: 1st (n =1120) |
|
| CVs, other UA X2: 2nd (n =1083) |
|
| CVs, other UA X2: 3rd (n =1017) |
|
| CVs, other UA X2: 4th (n =836) |
|
| CVs, other UA + same F: 1st (n =1120) |
|
| CVs, other UA + same F: 2nd (n =1083) |
|
| CVs, other UA + same F: 3rd (n =1017) |
|
| CVs, other UA + same F: 4th (n =836) |
|
| CVs, other UA + other F: 1st (n =1120) |
|
| CVs, other UA + other F: 2nd (n =1083) |
|
| CVs, other UA + other F: 3rd (n =1017) |
|
| CVs, other UA + other F: 4th (n =836) |
|
| CVs, other UA + O: 1st (n =1120) |
|
| CVs, other UA + O: 2nd (n =1083) |
|
| CVs, other UA + O: 3rd (n =1017) |
|
| CVs, other UA + O: 4th (n =836) |
|
| CVs, other UA + other UB: 1st (n =1120) |
|
| CVs, other UA + other UB: 2nd (n =1083) |
|
| CVs, other UA + other UB: 3rd (n =1017) |
|
| CVs, other UA + other UB: 4th (n =836) |
|
| CVs, other UA + same UB: 1st (n =1120) |
|
| CVs, other UA + same UB: 2nd (n =1083) |
|
| CVs, other UA + same UB: 3rd (n =1017) |
|
| CVs, other UA + same UB: 4th (n =836) |
|
| CVs, unknown X2: 1st (n =1120) |
|
| CVs, unknown X2: 2nd (n =1083) |
|
| CVs, unknown X2: 3rd (n =1017) |
|
| CVs, unknown X2: 4th (n =836) |
|
| CVs, same UA + other UA X2: 1st (n =1120) |
|
| CVs, same UA + other UA X2: 2nd (n=1083) |
|
| CVs, same UA + other UA X2: 3rd (n =1017) |
|
| CVs, same UA + other UA X2: 4th (n =836) |
|
| CVs, other UA + same UA X2: 1st (n =1120) |
|
| CVs, other UA + same UA X2: 2nd (n =1083) |
|
| CVs, other UA + same UA X2: 3rd (n =1017) |
|
| CVs, other UA + same UA X2: 4th (n =836) |
|
| CVs, other UA X2 + same F: 1st (n =1120) |
|
| CVs, other UA X2 + same F: 2nd (n =1083) |
|
| CVs, other UA X2 + same F: 3rd (n =1017) |
|
| CVs, other UA X2 + same F: 4th (n =836) |
|
| CVs, same UA X2 + other UA X2: 1st (n =1120) |
|
| CVs, same UA X2 + other UA X2: 2nd (n =1083) |
|
| CVs, same UA X2 + other UA X2: 3rd (n =1017) |
|
| CVs, same UA X2 + other UA X2: 4th (n=836) |
|
| CVs, other UA + same UA + other F X2: 1st (n=1120) |
|
| CVs, other UA + same UA + other F X2: 2nd (n=1083) |
|
| CVs, other UA + same UA + other F X2: 3rd (n=1017) |
|
| CVs, other UA + same UA + other F X2: 4th (n=836) |
|
| PVN7, R F; CVs, R UA + L UA: 1st (n =1120) |
|
| PVN7, R F; CVs, R UA + L UA: 2nd (n =1083) |
|
| PVN7, R F; CVs, R UA + L UA: 3rd (n =1017) |
|
| PVN7, R F; CVs, R UA + L UA: 4th (n =836) |
|
| PVN7, L F; CVs, L UA + R UA: 1st (n =1120) |
|
| PVN7, L F; CVs, L UA + R UA: 2nd (n =1083) |
|
| PVN7, L F; CVs, L UA + R UA: 3rd (n =1017) |
|
| PVN7, L F; CVs, L UA + R UA: 4th (n =836) |
|
| PVN7, F; CVs, same UA + other UA: 1st (n =1120) |
|
| PVN7, F; CVs, same UA + other UA: 2nd (n =1083) |
|
| PVN7, F; CVs, same UA + other UA: 3rd (n =1017) |
|
| PVN7, F; CVs, same UA + other UA: 4th (n =836) |
|
| PVN7, F; CVs, R UA + L UA: 1st (n =1120) |
|
| PVN7, F; CVs, R UA + L UA: 2nd (n =1083) |
|
| PVN7, F; CVs, R UA + L UA: 3rd (n =1017) |
|
| PVN7, F; CVs, R UA + L UA: 4th (n =836) |
|